Major progress is being made in vaccines against Respiratory Syncytial Virus (RSV), with multiple vaccine candidates currently in the clinical phase of development. Making an investment case for public sector financing of RSV vaccine will require estimation of burden, cost-effectiveness, and impact. The aim of this study is to determine the proportion, age distribution and clinical spectrum of RSV associated hospitalizations in children in Karachi, Pakistan. A three years prospective study was conducted at the Aga Khan University Hospital in Karachi, a city of 20 million in south Pakistan, from August 2009 to June 2012. Children less than five years old admitted with acute respiratory infections (ARI) were enrolled. Throat swabs were collected and tested for RSV using real-time PCR. Multivariable log binomial regression analysis was performed to identify the associated factors of RSV infection. Out of 1150 children enrolled, RSV was detected among 223 (19%). Highest rate of RSV detection was in young infants less than 3 months of age (48/168, 29%), which accounted for 22% of all RSV detected. Most common diagnosis in RSV positive infants (<12 months of age) was bronchiolitis followed by pneumonia, while in older children between the ages of one and 5 years of age, pneumonia and asthma were the most common diagnosis. Although identified year-round, RSV was most prevalent from August to October with peak in September, coinciding with the rainy season.
| INTRODUCTION
Respiratory Syncytial Virus (RSV) is the most important viral cause of severe acute respiratory infections (ARI) in children worldwide.
1 ARI account for approximately 2 million deaths per year in children globally, 70% of which are concentrated in Africa and South Asia. 2, 3 RSV associated deaths are estimated to be 66 000-199 000 in children under 5 years of age and 15-40% of pediatric hospitalizations with ARI in developing countries are attributable to RSV.
This makes RSV one of the leading targets of public health interventions.
1,4,5
The field of RSV vaccines is advancing at an unprecedented pace.
While more than 50 RSV vaccine candidates are currently in development, around ten candidates are either entering, or are already in, clinical trials. 6 Live attenuated approaches have been in protein. 7 The preliminary phase 2 results of RSV F nanoparticle vaccine made by Novavax show that immunizing mothers with this vaccine was safe for fetuses and could protect infants against RSV. 8 In order to make a case for vaccine introduction in resource-limited settings and guide the optimal vaccine delivery strategy, it is important to understand the morbidity and mortality risks of RSV associated hospitalizations in different age groups, particularly in settings with the highest burden of disease. With this goal in mind, we conducted a threeyear prospective surveillance study to determine the frequency, clinical features, and severity of RSV in children of different age groups hospitalized with ARI in a tertiary care hospital of Karachi, Pakistan. After discharge from the hospital, the medical records of all enrolled participants were reviewed and data about the inpatient workup, management and clinical course were recorded.
| METHODS

| Statistical Analysis
Descriptive analysis was performed to describe age of children and proportion of respiratory virus etiology. Associations between sociodemographic characteristics, seasonality, clinical manifestations, and RSV infection were assessed using univariable and multivariable log binomial regression analysis. All the variables found significant at P < 0.30 at the univariate level were tested simultaneously in the multivariable regression model. The final model with variables significant at 5% level of significance was selected using the best subset method. Crude and adjusted risk ratios with 95% confidence intervals were calculated. Statistical analysis was performed using Stata software (Version 11).
| RESULTS
A total of 3830 children less than 5 years old were admitted at Aga Khan University Hospital with ARI and associated diagnosis during the study period. Out of these, 30% had pneumonia, 25% had asthma, 24% had a URI, and 22% had bronchiolitis. Acute URI admissions peaked in February and were relatively lower in the months of June and July (Fig. 1) . This was more apparent in the A total of 1150 (33%) out of 3830 children were enrolled in the study. The proportion of RSV cases in various months varied from 2% to 43%. The cases started increasing in the month of July (14%) reaching the peak (43%) in September, and then slowly declining reaching to 8%
in the month of December. The rate of RSV positivity is lowest during January-February and highest during September-October (Fig. 2) . The most common admission diagnosis among those enrolled was pneumonia (38%) followed by bronchiolitis (28%), asthma (17%), and URI (13%). RSV was detected in 223(19%) of the enrolled children (Table 1) . Overall, 65% of the enrolled children were male with a slightly higher proportion among RSV negative children (66%) than RSV positive (62%). Children with RSV were relatively younger (median age 7; IQR 3-13 months) than RSV negative children (median 10; IQR 4.9-21 months). About 30% of the enrolled children had a smoker within the household with almost similar proportion between those with RSV positive and negative status. More than 85% of the enrolled children were presented with cough, followed by fever (73%), nasal congestion (69%), and shortness of breath (68%). About 2% of the children required intubation with slightly higher proportion among RSV positive cases than RSV negative (3.6% vs. 2%, respectively). In addition, 41(3.6%) children needed admission/transferred to the ICU and 22 children (1.9%) died during hospitalization (two among RSV positive and 20 among RSV negative). | 1153
The age-wise distribution of RSV and its detection rate is summarized in Table 2 . Of the 223 children testing positive for RSV, 148 were less than 12 months old (22% detection rate for RSV), 47
were between 12 and 24 months (18% detection rate) and 27 were between 24 and 60 months old (12% detection rate). During the first year, the highest detection rate was in young infants less than 3 months old (29%), followed by infants between 3 and 6 months of age (23%). Cough and nasal congestion were the predominant clinical features while fever was reported by parents in two third of the RSV positive cases across all age groups. Bronchiolitis was the leading discharge diagnosis in RSV positive children less than 12 months old, followed by pneumonia. Pneumonia was the most common diagnosis in RSV positive children between the ages of 1 and 5 years, followed by asthma exacerbation.
The multivariable regression analysis showed that the risk of RSV linearly decreases with increasing age (adjusted RR 1.81; 95%CI 14 RSV accounted for almost a third of the ARI associated hospitalizations in young infants less than 3 months old in our study. Risk of RSV among children less than 3 months of age hospitalized with ARI was almost 80% higher compared to those above 1 year of age. These findings are consistent with a study conducted in the USA by Hall et al, 4 showing the highest risk of RSV among children less than 5 months of age. The higher burden of disease in young infants has implications for the anticipated vaccine program. A future RSV vaccine which aims to protect infants in this age group, either through maternal immunization or immunization to the baby immediately after birth will likely have most public health impact.
We found that children with RSV infection were more likely to have post-tussive emesis and be diagnosed as bronchiolitis compared to children admitted for ARI but testing negative for RSV. Interestingly, children with RSV associated ARI were almost 4× more likely to be intubated compared to children who had a non-RSV associated ARI.
This increased severity of disease associated with RSV has been infrequently reported in the literature. 16 Two children enrolled in our study who had RSV associated ARI died, but the overall mortality rate was not different in RSV positive and RSV negative children. Of the two children who had RSV and died during hospitalization, one was 3.5 years old boy with Down's syndrome, ventricular septum defect and pulmonary hypertension, who died after 7 days of hospitalization in the ICU. Besides RSV, he was also found to have influenza and pseudomonas bacteremia. The second child was a 2 years 4 months old girl, born after 31 weeks gestation but otherwise previously healthy, who was hospitalized with pneumonia for 3 days, which included 1 day in the ICU requiring mechanical ventilation before her death.
Strengths of this study include PCR based testing for RSV, which is the gold standard and often not available outside research settings in the third world settings. Data was collected prospectively over 3 years, so seasonal inferences are likely valid. The study also had multiple limitations. Although our study has a relatively large sample size of 1150 infants, a significant proportion of the possibly eligible children were not enrolled. Major reasons for non-enrollment included unclear diagnosis at the time of admission, lack of surveillance during weekends, early discharge before the family could be approached for enrollment, delay of greater than 48 h in approaching family for enrollment (particularly when the patients were admitted over the weekend), and unavailability or refusal of parents to give consent.
Nonetheless, as the Figs. 1-3 show, the enrollment pattern followed the pattern of ARI admissions, so the seasonality and the relative 
